Ocugen, Inc. Q3 2025 Earnings Recap

Ocugen reported strong progress in its clinical development, with advancements in its gene therapy candidates OCU400 and OCU410ST, and secured additional funding to extend its operational runway.

Key Takeaways

• OCU400 is nearing completion of Phase 3 enrollment, with a Biological Licensing Application (BLA) submission planned for 1H 2026, targeting a significant unmet need in retinitis pigmentosa.
• A registered direct offering generated approximately $20 million, extending the company’s financial runway into mid-2026, with potential for an additional $30 million from warrants.
• Ocugen secured an exclusive licensing agreement for OCU400 in South Korea, with projected potential revenues exceeding $180 million in the first decade post-approval.
• OCU410ST's Phase 2/3 trial enrollment is ahead of schedule, aiming to address multiple genetic mutations associated with Stargardt disease, underscoring the high unmet medical need in this patient population.